We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 3

2.
Figure 3

Figure 3. CSF biomarker changes from baseline. From: A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease.

Baseline values and change from baseline (CBL) to weeks 24 and 78 for CSF Aβx-42 (left) and tau (right). Least squares (LS) means were compared using a repeated-measures analysis; median values were compared using Wilcoxon rank-sum test.

S. Salloway, et al. Neurology. 2011 September 27;77(13):1253-1262.
3.
Figure 2

Figure 2. Primary outcome measures: Changes from baseline. From: A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease.

Least squares (LS) mean changes from baseline for the coprimary outcome measures (Neuropsychological Test Battery [NTB] and Alzheimer's Disease Cooperative Study–Activities of Daily Living [ADCS-ADL]) in overall (Mini-Mental State Examination [MMSE] 16–26) modified intent-to-treat (mITT) (A, B) and per protocol set (PPS) (C, D) populations, and for mild Alzheimer disease (AD) subgroup (MMSE 23–26) mITT (E, F) and PPS (G, H) populations. For all panels: upward (positive) direction represents better performance, downward direction (negative) indicates worse performance. Changes from baseline to week 78 in the ELND005 (purple) and placebo (green) treatment groups noted on graph.

S. Salloway, et al. Neurology. 2011 September 27;77(13):1253-1262.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk